Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Saved in:
Main Authors: | Sam Gandy, David S. Knopman, Mary Sano |
---|---|
Format: | article |
Language: | EN |
Published: |
BMC
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Topical Insights Into the Post-Approval Controversies of Aducanumab
by: Dhiraj Kumar, et al.
Published: (2021) -
Is Aducanumab for LMICs? Promises and Challenges
by: Illangage P. C. Gunawardena, et al.
Published: (2021) -
Amyloid
Published: (1994) -
Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
by: Devika Sirohi, et al.
Published: (2017) -
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
by: Shuo Gu, et al.
Published: (2018)